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STAT3, a Key Parameter of  
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Case of experimental Acetaminophen 
(Paracetamol)-induced Liver Damage
Heiko Mühl*
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Acetaminophen (APAP, N-acetyl-p-aminophenol, or paracetamol) overdosing is a prev-
alent cause of acute liver injury. While clinical disease is initiated by overt parenchymal 
hepatocyte necrosis in response to the analgetic, course of intoxication is substantially 
influenced by associated activation of innate immunity. This process is supposed to 
be set in motion by release of danger-associated molecular patterns (DAMPs) from 
dying hepatocytes and is accompanied by an inflammatory cytokine response. Murine 
models of APAP-induced liver injury emphasize the complex role that DAMPs and 
cytokines play in promoting either hepatic pathogenesis or resolution and recovery 
from intoxication. Whereas the function of key inflammatory cytokines is controversially 
discussed, a subclass of specific cytokines capable of efficiently activating the hepato-
cyte signal transducer and activator of transcription (STAT)-3 pathway stands out as 
being consistently protective in murine models of APAP intoxication. Those include 
foremost interleukin (IL)-6, IL-11, IL-13, and IL-22. Above all, activation of STAT3 under 
the influence of these cytokines has the capability to drive hepatocyte compensatory 
proliferation, a key principle of the regenerating liver. Herein, the role of these specific 
cytokines during experimental APAP-induced liver injury is highlighted and discussed 
in a broader perspective. In hard-to-treat or at-risk patients, standard therapy may fail 
and APAP intoxication can proceed toward a fatal condition. Focused administration 
of recombinant STAT3-activating cytokines may evolve as novel therapeutic approach 
under those ill-fated conditions.
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inTRODUCTiOn
Acute liver injury (ALI) is a major burden of health care systems worldwide. Viral infections and side 
effects of pharmacotherapy stand out among pathological challenges provoking ALI. Specifically, 
overdosing of the weak-to-moderate analgesic acetaminophen (APAP; N-acetyl-p-aminophenol; 
or paracetamol) is regarded as one major cause of ALI in the developed countries. Notably, 
over-the-counter availability, underrated toxicity, and a narrow therapeutic margin further APAP 
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misuse/intoxication which, if not timely treated with its antidote 
N-acetylcysteine, can proceed toward a fulminant condition 
requiring transplantation for patient survival (1–3).
Specifically, APAP is hold responsible for up to 80,000 emer-
gency visits, 2500 hospitalizations and 500 fatal intoxications 
in the United States annually (2, 4). A recent study analyzing 
between 2005 and 2007 patients from selected European countries 
documented 114 drug overdose-related cases of ALI demanding 
transplantation (of 600 totals). Ninety-seven percent (111 cases) 
of those concerned APAP (5). In Germany, 850 hospitaliza-
tions due to APAP intake were recorded 2012 for patients with 
statutory health insurance. However, only four fatalities were 
documented (6). Altogether, epidemiological studies indicate 
noticeable variations in the incidence of severe APAP-induced 
ALI in different populations within Europe (5) and the developed 
countries altogether.
On a cellular level, liver injury by APAP is regarded a two-hit 
process involving initial direct induction of hepatocyte cell death 
and, subsequent to that, activation of innate immunity that trig-
gers an inflammatory response having the complex potential to 
either aggravate disease or to actually support tissue repair and 
hepatic regeneration (7–12).
Hepatocyte cell death, being at the root of APAP toxicity, is 
dependent on drug metabolizing cytochrome P450 enzymes 
(Cyp), particularly Cyp2e1 and Cyp1a2 (8, 13). These enzymes 
generate from APAP poisonous N-acetyl-p-benzoquinone imine 
(NAPQI), a highly reactive metabolite capable of coupling to 
protein sulfhydryl groups thereby disturbing hepatocyte cell 
physiology. Specifically, NAPQI mediates mitochondrial oxida-
tive stress, drop in ATP generation, c-jun N-terminal kinase 
(JNK) activation, and eventually cell death (8, 14). Although 
apoptosis and necrosis as well as necrosis-related necroptosis 
have all been detected during experimental APAP-induced ALI, 
the latter two types of cell demise prevail in the context of patho-
logical intoxication. Notably, as opposed to immune-deactivating 
apoptosis, necrosis and necroptosis connect to activation of innate 
immunity and inflammation (7, 8, 14, 15) whereby the leukocytic 
cell compartment becomes involved into course and outcome of 
APAP-induced ALI.
THe COMPLeX ROLe OF innATe 
iMMUniTY AnD inFLAMMATORY 
CYTOKineS in eXPeRiMenTAL MURine 
APAP-inDUCeD LiveR inJURY
Key to sterile necro-inflammation, as detected in APAP-induced 
ALI, is release of danger-associated molecular patterns (DAMPs) 
from cells undergoing necrosis. Once increasingly present in the 
extracellular compartment or later on taken up by leukocytes, 
those are detected by sensors of innate immunity, e.g., toll-like 
receptors (TLR), setting in motion inflammatory processes that 
can drive pathology but also setting the stage for parenchymal 
tissue repair and regeneration (9–12, 16, 17).
DAMPs reported to mediate pathological immunoactivation 
during APAP-induced ALI include high-mobility group box 1 
protein (HMGB1) (18–20) and histones (21). Both couple to 
TLR4 on hepatic monocytes/ macrophages, including resident 
Kupffer cells. Besides that, HMGB1 was found to activate 
the receptor for advanced glycation end product (RAGE) on 
neutrophils, whereas histones may mediate pathological effects 
also via TLR2. Nucleic acids released from necrotic hepatocytes 
likewise display a strong potential to aggravate APAP intoxica-
tion by action on TLR sensors. Specifically, DNA targeting TLR9 
(22, 23) and RNA targeting leukocytic or hepatocyte TLR3 
(24) contribute to hepatic injury. A pivotal role for TLR9 was 
confirmed by pharmacological application of a small-molecule 
TLR9 antagonist to mice undergoing APAP intoxication (25). 
Among DAMPs sensed independently from the TLR system, 
ATP and uric acid stand out. Both can aggravate APAP-induced 
ALI (26–28) supposedly by action on the inflammasome, a 
multiprotein complex consisting of interleukin (IL)-1β/IL-18-
activating caspase-1. In this scenario, ATP binds to purinergic 
P2X7 receptors on monocytes/macrophages (including Kupffer 
cells) at the hepatic microenvironment connecting to cellular 
K+-efflux and subsequent inflammasome activation. After being 
released by dying cells or derived from degradation of nucleic 
acids, uric acid, on the other hand, is taken up in the form of 
crystals that directly activate inflammasomes and, thus, IL-1β/
IL-18-dependent inflammation (29, 30).
Although, at first sight, it appears obvious that innate immunity 
and sterile inflammation amplify pathogenesis of APAP-induced 
ALI, this topic in fact is controversially discussed. For example, 
while several studies indicate a pathological role of TLR4 
(21, 31, 32), a recent report did not endorse a disease-promoting 
but rather a protective function of myeloid TLR4 signaling in 
APAP-related liver damage. Interestingly, deleterious action of 
RAGE and TLR9 was confirmed in this same study (33). Another 
recent report disputed a pathogenic role for P2X7 receptors in 
APAP intoxication (34). While some parameters, such as mice 
characteristics, including their microbiome (35), or APAP dos-
age cannot be fully ruled out as sources of discrepancies, those 
divergent observations may actually reflect janus-faced functions 
of innate immunity and sterile inflammation in APAP-induced 
ALI  –  aggravating tissue damage, likely at an early phase of 
disease, but simultaneously displaying the strong potential to 
initiate and perpetuate hepatic repair and regeneration (36). The 
unique ability of the liver to, upon injury, most efficiently initiate 
processes aiming at preservation of organ function is driven by 
initial hepatocyte hypertrophy (increase in size) and an adjacent 
proliferative phase enabling compensatory hyperplasia (37, 38). 
Notably, if hepatic damage stays below a pathological threshold, 
the regenerative capacity of the liver can fully restore organ func-
tion in response to APAP (39, 40).
The remarkable fact of quite divergent observations con-
cerning the role of sterile inflammation in APAP-induced 
ALI particularly applies to the function of nuclear factor-κB 
(NF-κB)-activating inflammatory cytokines that are induced 
adjacent– distal to innate sensing. This specifically holds true for 
prototypic IL-1 and tumor necrosis factor (TNF)-α (41), both 
produced during APAP-induced ALI (22, 24, 42–46). Whereas 
aggravation of disease by pretreatment of mice with recombinant 
TNFα is undisputed (47), modulation of endogenous TNFα 
biological activity, as achieved by administering neutralizing 
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antibodies or by investigating TNF receptor-1-deficient mice, 
resulted in quite heterogeneous outcome. Reports, on the one 
hand, demonstrate amelioration of APAP-induced toxicity 
by application of anti-TNFα antibodies (48, 49) or by using 
TNF receptor-1-deficient mice (49). By contrast, other reports 
observed either no effect of TNFα-neutralization (50, 51) or 
even aggravation of disease as detected using TNF receptor-
1-deficient mice (52, 53). Those latter two studies actually 
indicate a tissue-protective function of endogenous TNFα in 
APAP-induced ALI that coincides with enhanced hepatocyte 
proliferation and activation of the key pro-regenerative tran-
scription factor signal transducer and activator of transcription 
(STAT)-3 (54). To assess the role of IL-1 in APAP-toxicity is like-
wise puzzling. Either pathogenic functions (22, 55), no major 
role (42), or protection (56) by IL-1 has been put on record. The 
view that inflammatory cytokines, such as IL-1 and TNFα, have 
the potential to actually promote liver regeneration was recently 
extended to the IL-1 family member IL-36γ (57,  58). In fact, 
administration of IL-36 receptor antagonist and thus blockage 
of IL-36 biological activity during APAP-induced ALI impairs 
recovery in the late phase of intoxication (58). Interestingly, 
IL-36 mediating tissue protection likewise applies to intestinal 
healing (59, 60).
Altogether, current data support the concept that sterile 
inflammation and accompanied NF-κB-activating cytokines 
may promote hepatic repair and regeneration particularly in the 
later phase of APAP toxicity thereby affecting disease outcome 
(12). It is tempting to speculate that secondary induction of 
STAT3-activating cytokines, alike IL-6 (61), by NF-κB-activating 
cytokines essentially contributes to the vital process of restoring 
liver homeostasis in response to APAP.
STAT3 in HePATiC RePAiR AnD 
ReGeneRATiOn
STAT-3 is a member of the STAT family of transcription fac-
tors, which exerts decisive and context-dependent functions in 
inflammation, tissue survival, and carcinogenesis. Those char-
acteristically include promotion of anti-apoptosis, proliferation, 
and stress resistance. Efficient activation of STAT3 is achieved 
under the influence of specific cytokines displaying janus-kinase 
signaling but also by selected growth factors, among others 
epidermal and platelet-derived growth factor. Phosporylation at 
Tyr705 is regarded a hallmark of STAT3 activation that couples 
to protein dimerization, nuclear translocation, and regulation 
of gene expression (62–65). In addition, phosphorylation at 
Ser727 (63, 65) and/or protein acetylation (66) amplify, whereas 
S-nitrosylation at Cys259 (67) and/or protein sumoylation (68) 
curb STAT3 activity. As already alluded to, enforcing hepatocyte 
anti-apoptosis and proliferation is key to liver protection by 
STAT3. Those functions are achieved by upregulation of gene 
products pivotally involved in cell fate decisions, among others, 
B-cell lymphoma-extra large (bclxL), myeloid cell leukemia-1 
(mcl1), or survivin mediating anti-apoptosis as well as c-myc 
(myc), cyclin B1/D1 (ccnb1/ccnd1), or cyclin-dependent kinase-2 
(cdc2) mediating proliferation (62, 63).
The albumin-promoter was used to generate  hepatocyte- 
specific conditional STAT3 knockout mice in order to address the 
role of STAT3 in this cell type. Experiments revealed that hepato-
cyte STAT3 is, to a substantial part, accountable for hepatocyte 
proliferation and liver regeneration after murine partial hepa-
tectomy. Notably, hepatocyte c-myc expression is aberrant and 
its inducibility retarded in aforementioned conditional STAT3-
deficient mice undergoing this procedure (69). In a study using a 
similar approach, hepatocyte STAT3 was functionless regarding 
parameters of liver injury evaluated in early APAP-induced ALI. 
However, analysis in that study was performed only 6  h after 
APAP administration and, thus, in the initial phase of intoxica-
tion (70) – leaving open the question of STAT3 functions during 
the later repair/regeneration phase. Notably, increased STAT3 
activation in murine liver is still detectable 24  h after APAP 
application (71); the same holds true for expression of STAT3-
activating IL-6 (72, 73).
TiSSUe PROTeCTiOn BY  
STAT3-ACTivATinG CYTOKineS AS 
DeTeCTeD in APAP-inDUCeD ALi: iL-6, 
iL-11, iL-13, AnD iL-22 – AnD iL-10
Whereas the role of NF-κB-activating cytokines in APAP-
induced ALI appears complex and bewildering, STAT3-activating 
cytokines capable of directly targeting hepatocytes must be 
regarded as major drivers of liver regeneration. Those include 
IL-6, IL-11, IL-13, and IL-22.
Interleukin-6 is the flagship of a family of cytokines operating 
through transmembrane gp130 as signal transducing unit thereby 
coupling to activation of STAT transcription factors, in case of 
IL-6 foremost STAT3 (61). This also applies to its cytokine sibling 
IL-11 (74). Both, IL-6 and IL-11, are upregulated during initial 
hepatocyte injury and stay elevated, along with activated STAT3 
(71), in the repair/regeneration phase at 24 h after APAP admin-
istration to mice (72, 73). In fact, protection by endogenous IL-6 
was observed early on. Particularly in time-wise advanced disease 
24 h (73) or 48 h (75) after APAP administration, IL-6-deficient 
mice endure aggravated toxicity associated with low production of 
hepatocyte-associated proliferating cell nuclear antigen (PCNA) 
and weakened liver macrophage inflammatory protein-2 (MIP-2) 
expression (75). Both, PCNA and MIP-2 (76), are key parameters 
of hepatocyte proliferation under the influence of APAP. Those 
observations suggest impaired recovery upon lack of IL-6. As 
expected, treatment of IL-6 deficient mice with recombinant 
IL-6 attenuated retardation of repair and regeneration (75). It is 
noteworthy that hepatocytes are among the few non-leukocytic 
cell types expressing functional IL-6 receptors and, thus, allow 
classical IL-6 signaling. Despite this fact, recent data indicate that 
trans-signaling by soluble IL-6R/IL-6 complexes (61, 77) is essen-
tial for the function of this cytokine during APAP-induced ALI 
(78). In fact, specific blockage of IL-6 trans-signaling by sgp130Fc 
(77) substantially exacerbated disease (78); whereas pretreatment 
of mice with hyper-IL-6 (77), a recombinant agent specifically 
activating trans-signaling, ameliorated APAP toxicity – albeit to 
a more moderate degree (78).
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Interleukin-11 is a further STAT3-activating member of the 
IL-6 family directly targeting hepatocytes (74, 79) and, in stark 
contrast to IL-6, is efficiently expressed by inflamed/stressed 
hepatocytes under the influence of APAP (71). Autocrine or par-
acrine action may, thus, ensure high local IL-11 bioactivity that 
likely feeds back on the course of APAP-induced ALI. Notably, 
early data already revealed amelioration of murine APAP-toxicity 
by recombinant human IL-11 (80). This observation has been 
corroborated recently. A super-active modification of human 
IL-11 indeed enhanced protective hepatocyte compensatory 
proliferation in diseased mice. In female IL-11 receptor-deficient 
mice (IL11Ra−/−) aggravated toxicity and diminished hepatocyte 
proliferation indicate a significant role for endogenous IL-11 
during APAP-induced ALI. Interestingly, this observation does 
not apply to male IL11Ra−/− mice that actually display compensa-
tory augmentation of supposedly protective IL-6 (71). It should 
be emphasized that female mice, compared to males, generally 
display reduced sensitivity toward APAP that is connected to an 
enhanced capability in females to restore hepatocyte mitochon-
drial glutathione levels (81).
Interleukin-13 is renowned as key Th2 cytokine that, however, 
is produced by various cell types of foremost leukocytic origin. By 
binding to its heterodimeric IL-4Rα/IL-13Rα1 receptor complex, 
IL-13 activates STAT3 (along with STAT6) in even more diverse 
cell types (82), including murine hepatocytes (83). Elevated 
systemic levels of IL-13 are well-detectable at 4, 12, and 24  h 
after APAP administration to mice (51, 84). Notably, exacerbated 
disease connecting to IL-13 blockage by neutralizing antibodies 
or lack of bioactivity in knockout mice firmly indicates protec-
tion by this cytokine during APAP intoxication (51). Activation 
of hepatocyte STAT3 by IL-13 (83) suggests direct protective 
action during APAP-induced ALI. However, upregulation of the 
supposedly detrimental IL-12/IFNγ-axis (72) during intoxication 
in IL-13-deficient mice (51) additionally implicates macrophage-
addressing immunomodulatory functions of IL-13 (85). Whether 
administration of surplus recombinant IL-13 can ameliorate 
APAP-induced ALI has, to the best of our knowledge, not been 
investigated.
Interleukin-22 is mainly a lymphocyte-derived member 
of the IL-10 cytokine family that gained significant attention 
due to tissue-protective properties largely mediated by STAT3 
activation specifically in epithelial (-like) cells, including 
hepatocytes. Accordingly, IL-22 mediates favorable effects in 
various preclinical disease models affecting biological barriers 
at the lung, intestine, and liver. Notably, IL-22 generally does 
not activate leukocytes (86–88). A single dosage of recombinant 
IL-22 is actually sufficient to ameliorate APAP toxicity in mice 
(43, 70). Protection by IL-22 is dependent on STAT3 (70), does 
not involve modulation of APAP-metabolizing cytochrome 
P450 enzymes but is associated with increased compensatory 
hepatocyte proliferation (43). The role of endogenous IL-22 
during APAP-induced ALI has, to the best of our knowledge, 
not been investigated. Recently, a functionally relevant aspect of 
IL-22 biology attracted attention. A potent synergism between 
the IFN signaling system and IL-22 concerning activation of 
STAT1 was identified in human colon carcinoma cells, HepG2 
hepatoma cells, and primary keratinocytes on a biochemical level 
(89). In contrast to STAT3, STAT1 (e.g., activated by IFNγ) pro-
motes cell death, inhibits proliferation, is generally considered 
pro-inflammatory (90), and pathogenic in APAP-induced ALI 
(72). This regulatory path has recently been extended to murine 
in vivo pathology during viral infection (91) or graft-versus-host 
disease (92) and may affect the function of IL-22 not only under 
conditions of overt IFN production but likewise in the context of 
typ I IFN immunotherapy (90).
Interleukin-10 is a mainly leukocyte-derived protein that 
drops out of the list of aforementioned STAT3-activating 
cytokines because it is supposed to act foremost on leukocytic 
cells. IL-10 serves as principal deactivator of T cells and in 
particular of mononuclear phagocytes thereby modulating in 
STAT3-dependent manner inflammatory processes (93, 94) and 
holding in check potentially poisonous mediators, among oth-
ers inducible nitric oxide (NO) synthase (95) -derived NO (84). 
During APAP intoxication systemic levels and hepatic expression 
of IL-10 increase. Notably, IL-10 deficient mice display enhanced 
sensitivity to APAP-induced ALI, which is unrelated to APAP 
metabolism but detectable on the level of serum ALT, morpho-
logically, and by analysis of mortality rates (84). Since STAT3 can 
principally drive IL-10 expression (93, 96, 97), this regulatory path 
may possibly contribute to tissue protection by STAT3-activating 
cytokines, such as IL-6. However, the therapeutic potential of 
surplus exogenously applied IL-10 in APAP-induced ALI seems 
limited as administration of the recombinant cytokine failed to 
protect diseased mice (50).
Although this review focuses on cytokines efficiently targeting 
hepatocytes, it is important to note that modulation of murine 
APAP-induced ALI by endogenous IL-10 (and IL-13) unequivo-
cally indicate a pivotal function of STAT3 also in myeloid cells 
(monocytes/macrophages/Kupffer cells) for determining course 
and outcome of APAP intoxication. Besides addressing STAT3 in 
hepatocytes, hepatic myeloid STAT3, thus, certainly is a further 
promising target for development of therapeutic strategies aim-
ing at APAP-induced ALI.
TRAnSLATiOnAL/THeRAPeUTiC 
iMPLiCATiOnS AnD COnCLUSiOnS
Administering hepatocyte STAT3-activating cytokines emerges 
from preclinical studies as encouraging pharmacological strat-
egy that aims at hard-to-treat patients with APAP-induced ALI. 
Moreover, APAP intoxication may serve as paradigm for a whole 
group of injury-driven acute inflammatory liver diseases inde-
pendent on the nature of the initiating insult (54). To translate 
preclinical knowledge to clinical application is, however, in some 
cases advantaged in others complicated by specific properties 
ascribed to aforementioned cytokines.
Although IL-6 displays significant tissue-protective character-
istics, administration of the recombinant cytokine to patients is 
hampered by its pro-inflammatory effects especially on lympho-
cyte biology (61). Specifically, IL-6 promotes human IL-17 pro-
duction and associated Th17 differentiation (98). Notably, IL-17 is 
pathogenic in murine APAP-induced ALI (19). As IL-6-induced 
Th17 associates with compromised Treg functions (99–101) and, 
FiGURe 1 | Schematic illustration of major parameters contributing to 
course of experimental APAP-induced ALi.
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if applicable, pathological antibody production (102), current 
knowledge supports serious concerns that administration of IL-6 
to patients may initiate or enhance autoimmune inflammation.
Mice undergoing APAP toxicity did not benefit from 
exogenously provided IL-10 (50), which may likewise apply to 
human intoxication. As chief deactivator of leukocytes (93, 94), 
recombinant IL-10 should actually interfere with desired produc-
tion of potentially pro-regenerative factors. In fact, this has been 
demonstrated for IL-6 and TNFα production by human Kupffer 
cells under the influence of active TLR4 signaling (103).
Interleukin-11 and IL-22 are functionally related cytokines 
that efficiently activate hepatocyte STAT3 signaling and 
associated downstream gene expression. Both have been 
described to mediate tissue protection at host/environment 
interfaces, in particular at the digestive tract. For example, 
IL-11 (104, 105) and IL-22 (106, 107) display protective prop-
erties in Citrobacter rodentium-driven infectious as well as in 
trinitrobenzene sulfonic acid chemically induced experimental 
colitis. Accordingly, use of both cytokines is discussed, albeit 
with caution, for the treatment of inflammatory bowel diseases 
(108). Aforementioned liver protective properties of IL-11 and 
IL-22 are not restricted to APAP intoxication. Among others, 
experimental hepatic disorders mediated by reperfusion injury 
(109, 110) or administration of either carbon tetrachloride 
(111, 112) or concanavalin A (112, 113) likewise exposed 
beneficial effects of both cytokines. Although the role of 
IL-11 and IL-22 in liver repair/regeneration should primarily 
be mediated by STAT3, it must be stressed that activation of 
MAPK- and PI3K/Akt-pathways may support IL-11/IL-22 
action in this context (74, 86, 114). The feasibility of recom-
binant IL-11 therapy for the treatment of ALI is emphasized 
by its relatively favorable compatibility in clinical trials (115). 
In fact, recombinant IL-11 has been approved for the treat-
ment of severe thrombocytopenia by the US Food and Drug 
Administration (79). At dosages showing biological activity, 
F-652 [Generon (Shanghai) Corporation Ltd.], an IL-22-like 
biopharmaceutical agent consisting of a human  IL-22-Fc-fusion 
protein (116), is likewise reported to have a good safety profile 
as determined in a phase I study in healthy volunteers (http://
www.businesswire.com/news/home/20151123005647/en/
Generon-Collaborating-Mayo-Clinic-Initiate-Phase-IIa).
Pharmacotherapy of APAP-induced ALI must obviously 
be successful when initiated hours after ingestion. Whereas 
most studies assessed prophylactic treatment, therapeutic 
application has been investigated in a translational setting for 
IL-22. Specifically, when administered 2 h after APAP together 
with suboptimal N-acetylcysteine dosing, recombinant IL-22 
improved murine intoxication (43). Notably, IL-22 application 
2 h post-APAP is after the drop of cellular glutathione as well as 
the onset of APAP-adduct formation and liver necrosis (43, 117). 
More studies on treatment timing, however, are needed before 
experimental models can be translated to clinical intoxication.
Altogether, APAP-induced ALI is a complex disorder deter-
mined by the extent of initial hepatotoxicity, by the nature of 
adjacent sterile inflammation, and by the actual regenerative 
potential of the liver at the time of injury (Figure 1). Preclinical 
data suggest that providing recombinant STAT3-activating 
cytokines directly targeting hepatocytes, especially IL-11 and 
IL-22, may evolve as additional novel pro-regenerative thera-
peutic option in hard-to-treat patients where standard therapy 
with N-acetylcysteine alone falls short. Notably, the benefit of 
focused short-term application of IL-11 or IL-22 in acute dis-
orders, such as APAP-induced ALI, should likely outweigh the 
inherent danger of these cytokines to promote in the long run 
tumor growth (74, 86, 118), which has been detected for IL-22 
and hepatocellular carcinoma patients (118–120).
AUTHOR COnTRiBUTiOnS
The author confirms being the sole contributor of this work and 
approved it for publication.
FUnDinG
The work of the author is supported by a grant from the DFG 
(MU 1284/6-1).
ReFeRenCeS
1. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 
(2010) 376(9736):190–201. doi:10.1016/S0140-6736(10)60274-7 
2. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: low-
ering the risks of hepatic failure. Hepatology (2004) 40(1):6–9. doi:10.1002/
hep.20293 
3. Brune K, Renner B, Tiegs G. Acetaminophen/paracetamol: a history of errors, 
failures and false decisions. Eur J Pain (2015) 19(7):953–65. doi:10.1002/ejp.621 
4. Budnitz DS, Lovegrove MC, Crosby AE. Emergency department visits for 
overdoses of acetaminophen-containing products. Am J Prev Med (2011) 
40(6):585–92. doi:10.1016/j.amepre.2011.02.026 
5. Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, et al. 
Liver transplant associated with paracetamol overdose: results from the 
seven-country SALT study. Br J Clin Pharmacol (2015) 80(3):599–606. 
doi:10.1111/bcp.12635 
6. Rotthauwe J. Wirksamkeit und Risiken von Paracetamol. Bulletin zur 
Arzneimittelsicherheit (2012) 3:11–3. 
6Mühl STAT3 Resolving APAP-Induced Liver Injury
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 163
7. Bantel H, Schulze-Osthoff K. Mechanisms of cell death in acute liver failure. 
Front Physiol (2012) 3:79. doi:10.3389/fphys.2012.00079 
8. Jaeschke H, Xie Y, McGill MR. Acetaminophen-induced liver injury: 
from animal models to humans. J Clin Transl Hepatol (2014) 2(3):153–61. 
doi:10.14218/JCTH.2014.00014 
9. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 
(2012) 143(5):1158–72. doi:10.1053/j.gastro.2012.09.008 
10. Maher JJ. DAMPs ramp up drug toxicity. J Clin Invest (2009) 119(2):246–9. 
11. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals 
in liver inflammation. J Hepatol (2013) 59(3):583–94. doi:10.1016/j.
jhep.2013.03.033 
12. Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hep-
atotoxicity and repair: the role of sterile inflammation and innate immunity. 
Liver Int (2012) 32(1):8–20. doi:10.1111/j.1478-3231.2011.02501.x 
13. Zaher H, Buters JT, Ward JM, Bruno MK, Lucas AM, Stern ST, et al. Protection 
against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. 
Toxicol Appl Pharmacol (1998) 152(1):193–9. doi:10.1006/taap.1998.8501 
14. Hinson JA, Roberts DW, James LP. Mechanisms of  acetaminophen-induced 
liver necrosis. Handb Exp Pharmacol (2010) 196:369–405. 
doi:10.1007/978-3-642-00663-0_12 
15. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in 
liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 
147(4):765.e–83.e. doi:10.1053/j.gastro.2014.07.018 
16. Matzinger P. The danger model: a renewed sense of self. Science (2002) 
296(5566):301–5. doi:10.1126/science.1071059 
17. Vénéreau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front 
Immunol (2015) 6:422. doi:10.3389/fimmu.2015.00422 
18. Huebener P, Pradere JP, Hernandez C, Gwak GY, Caviglia JM, Mu X, et al. 
The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification 
following necrosis. J Clin Invest (2015) 125(2):539–50. doi:10.1172/JCI76887 
19. Wang X, Sun R, Wei H, Tian Z. High-mobility group box 1 (HMGB1)-Toll-
like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced dam-
age-associated lethal hepatitis: interaction of γδ T cells with macrophages. 
Hepatology (2013) 57(1):373–84. doi:10.1002/hep.25982 
20. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, et al. Mechanistic 
biomarkers provide early and sensitive detection of acetaminophen-induced 
acute liver injury at first presentation to hospital. Hepatology (2013) 
58(2):777–87. doi:10.1002/hep.26294 
21. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones 
are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. 
J Immunol (2011) 187(5):2626–31. doi:10.4049/jimmunol.1003930 
22. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, 
Sutterwala FS, et  al. Acetaminophen-induced hepatotoxicity in mice is 
dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest (2009) 
119(2):305–14. doi:10.1172/JCI35958 
23. Marques PE, Oliveira AG, Pereira RV, David BA, Gomides LF, Saraiva AM, 
et al. Hepatic DNA deposition drives drug-induced liver injury and inflam-
mation in mice. Hepatology (2015) 61(1):348–60. doi:10.1002/hep.27216 
24. Cavassani KA, Moreira AP, Habiel D, Ito T, Coelho AL, Allen RM, et al. Toll 
like receptor 3 plays a critical role in the progression and severity of acetamin-
ophen-induced hepatotoxicity. PLoS One (2013) 8(6):e65899. doi:10.1371/
journal.pone.0065899 
25. Hoque R, Farooq A, Malik A, Trawick BN, Berberich DW, McClurg JP, et al.  
A novel small-molecule enantiomeric analogue of traditional (-)-morph-
inans has specific TLR9 antagonist properties and reduces sterile 
 inflammation-induced organ damage. J Immunol (2013) 190(8):4297–304. 
doi:10.4049/jimmunol.1202184 
26. Hoque R, Sohail MA, Salhanick S, Malik AF, Ghani A, Robson SC, et al. P2X7 
receptor-mediated purinergic signaling promotes liver injury in acetamino-
phen hepatotoxicity in mice. Am J Physiol Gastrointest Liver Physiol (2012) 
302(10):G1171–9. doi:10.1152/ajpgi.00352.2011 
27. Kono H, Chen CJ, Ontiveros F, Rock KL. Uric acid promotes an acute 
inflammatory response to sterile cell death in mice. J Clin Invest (2010) 
120(6):1939–49. doi:10.1172/JCI40124 
28. Kataoka H, Yang K, Rock KL. The xanthine oxidase inhibitor Febuxostat 
reduces tissue uric acid content and inhibits injury-induced inflammation 
in the liver and lung. Eur J Pharmacol (2015) 746:174–9. doi:10.1016/j.
ejphar.2014.11.013 
29. Gombault A, Baron L, Couillin I. ATP release and purinergic signaling in 
NLRP3 inflammasome activation. Front Immunol (2013) 3:414. doi:10.3389/
fimmu.2012.00414 
30. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. 
Immunol Rev (2010) 233(1):218–32. doi:10.1111/j.0105-2896.2009.00860.x 
31. Yohe HC, O’Hara KA, Hunt JA, Kitzmiller TJ, Wood SG, Bement JL, et al. 
Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. Am 
J Physiol Gastrointest Liver Physiol (2006) 290(6):G1269–79. doi:10.1152/
ajpgi.00239.2005 
32. Shah N, Montes de Oca M, Jover-Cobos M, Tanamoto K, Muroi M, 
Sugiyama  K, et  al. Role of toll-like receptor 4 in mediating multiorgan 
dysfunction in mice with acetaminophen induced acute liver failure. Liver 
Transpl (2013) 19(7):751–61. doi:10.1002/lt.23655 
33. Cai C, Huang H, Whelan S, Liu L, Kautza B, Luciano J, et  al. Benzyl 
alcohol attenuates acetaminophen-induced acute liver injury in a Toll-like 
receptor-4-dependent pattern in mice. Hepatology (2014) 60(3):990–1002. 
doi:10.1002/hep.27201 
34. Kataoka H, Kono H, Patel Z, Kimura Y, Rock KL. Evaluation of the con-
tribution of multiple DAMPs and DAMP receptors in cell death-induced 
sterile inflammatory responses. PLoS One (2014) 9(8):e104741. doi:10.1371/
journal.pone.0104741 
35. Schnabl B, Brenner DA. Interactions between the intestinal microbiome 
and liver diseases. Gastroenterology (2014) 146(6):1513–24. doi:10.1053/j.
gastro.2014.01.020 
36. Böhm F, Köhler UA, Speicher T, Werner S. Regulation of liver regeneration 
by growth factors and cytokines. EMBO Mol Med (2010) 2(8):294–305. 
doi:10.1002/emmm.201000085 
37. Fujiyoshi M, Ozaki M. Molecular mechanisms of liver regeneration and 
protection for treatment of liver dysfunction and diseases. J Hepatobiliary 
Pancreat Sci (2011) 18(1):13–22. doi:10.1007/s00534-010-0304-2 
38. Miyaoka Y, Miyajima A. To divide or not to divide: revisiting liver regenera-
tion. Cell Div (2013) 8(1):8. doi:10.1186/1747-1028-8-8 
39. Bhushan B, Walesky C, Manley M, Gallagher T, Borude P, Edwards G, et al. 
Pro-regenerative signaling after acetaminophen-induced acute liver injury 
in mice identified using a novel incremental dose model. Am J Pathol (2014) 
184(11):3013–25. doi:10.1016/j.ajpath.2014.07.019 
40. Lesna M, Watson AJ, Douglas AP, Hamlyn AN, James OF. Evaluation of 
paracetamol-induced damage in liver biopsies. Acute changes and fol-
low-up findings. Virchows Arch A Pathol Anat Histol (1976) 370(4):333–44. 
doi:10.1007/BF00445778 
41. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as media-
tors in the pathogenesis of septic shock. Chest (1997) 112(6 Suppl):321S–9S. 
doi:10.1378/chest.112.6_Supplement.321S 
42. Williams CD, Farhood A, Jaeschke H. Role of caspase-1 and interleukin-1beta 
in acetaminophen-induced hepatic inflammation and liver injury. Toxicol 
Appl Pharmacol (2010) 247(3):169–78. doi:10.1016/j.taap.2010.07.004 
43. Scheiermann P, Bachmann M, Goren I, Zwissler B, Pfeilschifter J, Mühl H. 
Application of interleukin-22 mediates protection in experimental acet-
aminophen-induced acute liver injury. Am J Pathol (2013) 182(4):1107–13. 
doi:10.1016/j.ajpath.2012.12.010 
44. Dragomir AC, Sun R, Choi H, Laskin JD, Laskin DL. Role of galectin-3 in 
classical and alternative macrophage activation in the liver following acet-
aminophen intoxication. J Immunol (2012) 189(12):5934–41. doi:10.4049/
jimmunol.1201851 
45. Henderson NC, Pollock KJ, Frew J, Mackinnon AC, Flavell RA, Davis  RJ, 
et al. Critical role of c-jun (NH2) terminal kinase in  paracetamol-induced 
acute liver failure. Gut (2007) 56(7):982–90. doi:10.1136/gut. 
2006.104372 
46. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a 
critical role in determining the progression and severity of acetaminophen 
hepatotoxicity. Gastroenterology (2004) 127(6):1760–74. doi:10.1053/j.
gastro.2004.08.053 
47. Gandhi A, Guo T, Ghose R. Role of c-Jun N-terminal kinase (JNK) in 
regulating tumor necrosis factor-alpha (TNF-alpha) mediated increase 
of acetaminophen (APAP) and chlorpromazine (CPZ) toxicity in murine 
hepatocytes. J Toxicol Sci (2010) 35(2):163–73. doi:10.2131/jts.35.163 
48. Blazka ME, Elwell MR, Holladay SD, Wilson RE, Luster MI. Histopathology 
of acetaminophen-induced liver changes: role of interleukin 1 alpha 
7Mühl STAT3 Resolving APAP-Induced Liver Injury
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 163
and tumor necrosis factor alpha. Toxicol Pathol (1996) 24(2):181–9. 
doi:10.1177/019262339602400206 
49. Ishida Y, Kondo T, Tsuneyama K, Lu P, Takayasu T, Mukaida N. The patho-
genic roles of tumor necrosis factor receptor p55 in  acetaminophen-induced 
liver injury in mice. J Leukoc Biol (2004) 75(1):59–67. doi:10.1189/ 
jlb.0403152 
50. Simpson KJ, Lukacs NW, McGregor AH, Harrison DJ, Strieter RM, 
Kunkel SL. Inhibition of tumour necrosis factor alpha does not prevent 
experimental paracetamol-induced hepatic necrosis. J Pathol (2000) 
190(4):489–94. doi:10.1002/(SICI)1096-9896(200003)190:4<489::AID 
-PATH534>3.3.CO;2-M 
51. Yee SB, Bourdi M, Masson MJ, Pohl LR. Hepatoprotective role of endogenous 
interleukin-13 in a murine model of acetaminophen-induced liver disease. 
Chem Res Toxicol (2007) 20(5):734–44. doi:10.1021/tx600349f 
52. Chiu H, Gardner CR, Dambach DM, Durham SK, Brittingham JA, Laskin JD, 
et al. Role of tumor necrosis factor receptor 1 (p55) in hepatocyte prolifera-
tion during acetaminophen-induced toxicity in mice. Toxicol Appl Pharmacol 
(2003) 193(2):218–27. doi:10.1016/j.taap.2003.07.003 
53. James LP, Kurten RC, Lamps LW, McCullough S, Hinson JA. Tumour 
necrosis factor receptor 1 and hepatocyte regeneration in acetaminophen 
toxicity: a kinetic study of proliferating cell nuclear antigen and cytokine 
expression. Basic Clin Pharmacol Toxicol (2005) 97(1):8–14. doi:10.111
1/j.1742-7843.2005.pto_97102.x 
54. Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of tran-
scription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci (2011) 
7(5):536–50. doi:10.7150/ijbs.7.536 
55. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification 
of a key pathway required for the sterile inflammatory response triggered by 
dying cells. Nat Med (2007) 13(7):851–6. doi:10.1038/nm1603 
56. Ishibe T, Kimura A, Ishida Y, Takayasu T, Hayashi T, Tsuneyama K, et  al. 
Reduced acetaminophen-induced liver injury in mice by genetic disruption 
of IL-1 receptor antagonist. Lab Invest (2009) 89(1):68–79. doi:10.1038/
labinvest.2008.110 
57. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in 
homeostasis and pathological conditions. J Leukoc Biol (2015) 97(4):645–52. 
doi:10.1189/jlb.3RI1014-495R 
58. Scheiermann P, Bachmann M, Härdle L, Pleli T, Piiper A, Zwissler B, et al. 
Application of IL-36 receptor antagonist weakens CCL20 expression and 
impairs recovery in the late phase of murine acetaminophen-induced liver 
injury. Sci Rep (2015) 5:8521. doi:10.1038/srep08521 
59. Medina-Contreras O, Harusato A, Nishio H, Flannigan KL, Ngo V, Leoni G, 
et al. Cutting edge: IL-36 receptor promotes resolution of intestinal damage. 
J Immunol (2016) 196(1):34–8. doi:10.4049/jimmunol.1501312 
60. Scheibe K, Backert I, Wirtz S, Hueber A, Schett G, Vieth M, et al. IL-36R 
signalling activates intestinal epithelial cells and fibroblasts and promotes 
mucosal healing in vivo. Gut (2016). doi:10.1136/gutjnl-2015-310374 
61. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and 
disease. Cold Spring Harb Perspect Biol (2014) 6(10):a016295. doi:10.1101/
cshperspect.a016295 
62. Yu H, Jove R. The STATs of cancer – new molecular targets come of age. Nat 
Rev Cancer (2004) 4(2):97–105. doi:10.1038/nrc1275 
63. Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to 
epithelial cancer  –  more than a “gut” feeling? Cell Div (2010) 5:14. 
doi:10.1186/1747-1028-5-14 
64. Qi QR, Yang ZM. Regulation and function of signal transducer and activator 
of transcription 3. World J Biol Chem (2014) 5(2):231–9. doi:10.4331/wjbc.
v5.i2.231 
65. Rébé C, Végran F, Berger H, Ghiringhelli F. STAT3 activation: a key factor in 
tumor immunoescape. JAKSTAT (2013) 2(1):e23010. doi:10.4161/jkst.23010 
66. Zhuang S. Regulation of STAT signaling by acetylation. Cell Signal (2013) 
25(9):1924–31. doi:10.1016/j.cellsig.2013.05.007 
67. Kim J, Won JS, Singh AK, Sharma AK, Singh I. STAT3 regulation by 
S-nitrosylation: implication for inflammatory disease. Antioxid Redox Signal 
(2014) 20(16):2514–27. doi:10.1089/ars.2013.5223 
68. Droescher M, Begitt A, Marg A, Zacharias M, Vinkemeier U. Cytokine-
induced paracrystals prolong the activity of signal transducers and activators 
of transcription (STAT) and provide a model for the regulation of protein 
solubility by small ubiquitin-like modifier (SUMO). J Biol Chem (2011) 
286(21):18731–46. doi:10.1074/jbc.M111.235978 
69. Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT3 contributes to the mito-
genic response of hepatocytes during liver regeneration. J Biol Chem (2002) 
277(32):28411–7. doi:10.1074/jbc.M202807200 
70. Feng D, Wang Y, Wang H, Weng H, Kong X, Martin-Murphy BV, et  al. 
Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. 
J Immunol (2014) 193(5):2512–8. doi:10.4049/jimmunol.1400588 
71. Nishina T, Komazawa-Sakon S, Yanaka S, Piao X, Zheng DM, Piao JH, et al. 
Interleukin-11 links oxidative stress and compensatory proliferation. Sci 
Signal (2012) 5(207):ra5. doi:10.1126/scisignal.2002056 
72. Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. A pivotal 
involvement of IFN-gamma in the pathogenesis of acetaminophen-induced 
acute liver injury. FASEB J (2002) 16(10):1227–36. doi:10.1096/fj.02-0046com 
73. Masubuchi Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR. Role of 
interleukin-6 in hepatic heat shock protein expression and protection against 
acetaminophen-induced liver disease. Biochem Biophys Res Commun (2003) 
304(1):207–12. doi:10.1016/S0006-291X(03)00572-2 
74. Ernst M, Putoczki TL. Molecular pathways: IL11 as a tumor-promoting 
cytokine-translational implications for cancers. Clin Cancer Res (2014) 
20(22):5579–88. doi:10.1158/1078-0432.CCR-13-2492 
75. James LP, Lamps LW, McCullough S, Hinson JA. Interleukin 6 and hepatocyte 
regeneration in acetaminophen toxicity in the mouse. Biochem Biophys Res 
Commun (2003) 309(4):857–63. doi:10.1016/j.bbrc.2003.08.085 
76. Hogaboam CM, Bone-Larson CL, Steinhauser ML, Lukacs NW, Colletti LM, 
Simpson KJ, et  al. Novel CXCR2-dependent liver regenerative qualities of 
ELR-containing CXC chemokines. FASEB J (1999) 13(12):1565–74. 
77. Drucker C, Gewiese J, Malchow S, Scheller J, Rose-John S. Impact of 
interleukin-6 classic- and trans-signaling on liver damage and regeneration. 
J Autoimmun (2010) 34(1):29–37. doi:10.1016/j.jaut.2009.08.003 
78. Li SQ, Zhu S, Han HM, Lu HJ, Meng HY. IL-6 trans-signaling plays important 
protective roles in acute liver injury induced by acetaminophen in mice. 
J Biochem Mol Toxicol (2015) 29(6):288–97. doi:10.1002/jbt.21708 
79. Garbers C, Scheller J. Interleukin-6 and interleukin-11: same same but 
different. Biol Chem (2013) 394(9):1145–61. doi:10.1515/hsz-2013-0166 
80. Trepicchio WL, Bozza M, Bouchard P, Dorner AJ. Protective effect of rhIL-11 
in a murine model of acetaminophen-induced hepatotoxicity. Toxicol Pathol 
(2001) 29(2):242–9. doi:10.1080/019262301317052521 
81. Du K, Williams CD, McGill MR, Jaeschke H. Lower susceptibility of female 
mice to acetaminophen hepatotoxicity: role of mitochondrial glutathione, 
oxidant stress and c-jun N-terminal kinase. Toxicol Appl Pharmacol (2014) 
281(1):58–66. doi:10.1016/j.taap.2014.09.002 
82. May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine 
(2015) 75(1):89–116. doi:10.1016/j.cyto.2015.05.018 
83. Stanya KJ, Jacobi D, Liu S, Bhargava P, Dai L, Gangl MR, et al. Direct control 
of hepatic glucose production by interleukin-13 in mice. J Clin Invest (2013) 
123(1):261–71. doi:10.1172/JCI64941 
84. Bourdi M, Masubuchi Y, Reilly TP, Amouzadeh HR, Martin JL, George JW, 
et  al. Protection against acetaminophen-induced liver injury and lethality 
by interleukin 10: role of inducible nitric oxide synthase. Hepatology (2002) 
35(2):289–98. doi:10.1053/jhep.2002.30956 
85. Doherty TM, Kastelein R, Menon S, Andrade S, Coffman RL. Modulation of 
murine macrophage function by IL-13. J Immunol (1993) 151(12):7151–60. 
86. Mühl H, Scheiermann P, Bachmann M, Härdle L, Heinrichs A, Pfeilschifter 
J. IL-22 in tissue-protective therapy. Br J Pharmacol (2013) 169(4):761–71. 
doi:10.1111/bph.12196 
87. Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 
system. Nat Rev Drug Discov (2014) 13(1):21–38. doi:10.1038/nrd4176 
88. Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobi-
ology and pathology. Annu Rev Immunol (2015) 33:747–85. doi:10.1146/
annurev-immunol-032414-112123 
89. Bachmann M, Ulziibat S, Härdle L, Pfeilschifter J, Mühl H. IFNα converts 
IL-22 into a cytokine efficiently activating STAT1 and its downstream 
targets. Biochem Pharmacol (2013) 85(3):396–403. doi:10.1016/j.
bcp.2012.11.004 
90. Mühl H. Pro-inflammatory signaling by IL-10 and IL-22: bad habit stirred up 
by interferons? Front Immunol (2013) 4:18. doi:10.3389/fimmu.2013.00018 
91. Hernández PP, Mahlakõiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, 
et al. Interferon-λ and interleukin 22 act synergistically for the induction of 
interferon-stimulated genes and control of rotavirus infection. Nat Immunol 
(2015) 16(7):698–707. doi:10.1038/ni.3180 
8Mühl STAT3 Resolving APAP-Induced Liver Injury
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 163
92. Lamarthée B, Malard F, Gamonet C, Bossard C, Couturier M, Renauld 
JC, et  al. Donor interleukin-22 and host type I interferon signaling 
pathway participate in intestinal graft-versus-host disease via STAT1 acti-
vation and CXCL10. Mucosal Immunol (2016) 9(2):309–21. doi:10.1038/ 
mi.2015.61 
93. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and func-
tions of the IL-10 family of cytokines in inflammation and disease. Annu Rev 
Immunol (2011) 29:71–109. doi:10.1146/annurev-immunol-031210-101312 
94. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted rela-
tionship between IL-10 and adaptive immunity: putting together the pieces 
of a puzzle. Cytokine Growth Factor Rev (2004) 15(1):61–76. doi:10.1016/j.
cytogfr.2003.11.001 
95. Mühl H, Bachmann M, Pfeilschifter J. Inducible NO synthase and antibacte-
rial host defence in times of Th17/Th22/T22 immunity. Cell Microbiol (2011) 
13(3):340–8. doi:10.1111/j.1462-5822.2010.01559.x 
96. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, et al. 
Interleukins 27 and 6 induce STAT3-mediated T cell production of interleu-
kin 10. Nat Immunol (2007) 8(12):1363–71. doi:10.1038/ni1537 
97. Kinjyo I, Inoue H, Hamano S, Fukuyama S, Yoshimura T, Koga K, et  al. 
Loss of SOCS3 in T helper cells resulted in reduced immune responses and 
hyperproduction of interleukin 10 and transforming growth factor-beta 1. 
J Exp Med (2006) 203(4):1021–31. doi:10.1084/jem.20052333 
98. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 
1beta and 6 but not transforming growth factor-beta are essential for the dif-
ferentiation of interleukin 17-producing human T helper cells. Nat Immunol 
(2007) 8(9):942–9. doi:10.1038/ni1496 
99. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, 
Cooper  KD. IL-6 signaling in psoriasis prevents immune suppression 
by regulatory T cells. J Immunol (2009) 183(5):3170–6. doi:10.4049/
jimmunol.0803721 
100. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, et al. 
Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell 
imbalance in patients with rheumatoid arthritis. Arthritis Rheum (2012) 
64(8):2499–503. doi:10.1002/art.34477 
101. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 
(2010) 40(7):1830–5. doi:10.1002/eji.201040391 
102. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin 
Pract Rheumatol (2006) 2(11):619–26. doi:10.1038/ncprheum0372 
103. Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Büschenfelde KH, Gerken G. 
Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) 
challenge. J Hepatol (1995) 22(2):226–9. doi:10.1016/0168-8278(95)80433-1 
104. Gibson DL, Montero M, Ropeleski MJ, Bergstrom KS, Ma C, Ghosh S, et al. 
Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and 
restores intestinal STAT3 signaling. Gastroenterology (2010) 139(4):1277–88. 
doi:10.1053/j.gastro.2010.06.057 
105. Qiu BS, Pfeiffer CJ, Keith JC Jr. Protection by recombinant human interleu-
kin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci (1996) 
41(8):1625–30. doi:10.1007/BF02087911 
106. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 
mediates early host defense against attaching and effacing bacterial patho-
gens. Nat Med (2008) 14(3):282–9. doi:10.1038/nm1720 
107. Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, et  al. Aryl 
hydrocarbon receptor-induced signals up-regulate IL-22 production and 
inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 
141(1):237–48.e1. doi:10.1053/j.gastro.2011.04.007 
108. Nguyen PM, Putoczki TL, Ernst M. STAT3-activating cytokines: a therapeu-
tic opportunity for inflammatory bowel disease? J Interferon Cytokine Res 
(2015) 35(5):340–50. doi:10.1089/jir.2014.0225 
109. Zhu M, Lu B, Cao Q, Wu Z, Xu Z, Li W, et al. IL-11 attenuates liver ischemia/
reperfusion injury (IRI) through STAT3 Signaling Pathway in Mice. PLoS 
One (2015) 10(5):e0126296. doi:10.1371/journal.pone.0126296 
110. Chestovich PJ, Uchida Y, Chang W, Ajalat M, Lassman C, Sabat R, 
et  al. Interleukin-22: implications for liver ischemia-reperfusion injury. 
Transplantation (2012) 93(5):485–92. doi:10.1097/TP.0b013e3182449136 
111. Kuhara T, Tanaka A, Yamauchi K, Iwatsuki K. Bovine lactoferrin ingestion 
protects against inflammation via IL-11 induction in the small intestine 
of mice with hepatitis. Br J Nutr (2014) 111(10):1801–10. doi:10.1017/
S0007114513004315 
112. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a 
protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor 
for hepatocytes via STAT3 activation. Hepatology (2004) 39(5):1332–42. 
doi:10.1002/hep.20184 
113. Bozza M, Bliss JL, Maylor R, Erickson J, Donnelly L, Bouchard P, et  al. 
Interleukin-11 reduces T-cell-dependent experimental liver injury in mice. 
Hepatology (1999) 30(6):1441–7. doi:10.1002/hep.510300616 
114. Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS, et  al. 
IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpres-
sion in vitro. Am J Physiol Gastrointest Liver Physiol (2007) 292(4):G1019–28. 
doi:10.1152/ajpgi.00239.2006 
115. Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, 
Breeden  E, et  al. A phase I trial of recombinant human interleukin-11 
(neumega rhIL-11 growth factor) in women with breast cancer receiving 
chemotherapy. Blood (1996) 87(9):3615–24. 
116. Lindemans CA, Calafiore M, Mertelsmann AM, O’Connor MH, Dudakov JA, 
Jenq RR, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithe-
lial regeneration. Nature (2015) 528(7583):560–4. doi:10.1038/nature16460 
117. Roberts DW, Bucci TJ, Benson RW, Warbritton AR, McRae TA, Pumford NR, 
et al. Immunohistochemical localization and quantification of the 3-(cyste-
in-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity. 
Am J Pathol (1991) 138(2):359–71. 
118. Lim C, Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine 
Growth Factor Rev (2014) 25(3):257–71. doi:10.1016/j.cytogfr.2014.04.005 
119. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, et al. Interleukin-22 promotes 
human hepatocellular carcinoma by activation of STAT3. Hepatology (2011) 
54(3):900–9. doi:10.1002/hep.24486 
120. Waidmann O, Kronenberger B, Scheiermann P, Köberle V, Mühl H, Piiper A. 
Interleukin-22 serum levels are a negative prognostic indicator in patients 
with hepatocellular carcinoma. Hepatology (2014) 59(3):1207. doi:10.1002/
hep.26528 
Conflict of Interest Statement: The author declares that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Mühl. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
